← Back to Search

Phototherapy

UVA1 Phototherapy for Vitiligo

Phase 2

Waitlist Available

Led By Harvey Lui, MD, FRCPC

Research Sponsored by University of British Columbia

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age > 18 years

Localized or generalized vitiligo that involves a non-mucosal or acral site

Must not have

History of severe medical illness or immunosuppression

Patients known to have a photosensitivity disorder

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

No Placebo-Only Group

Summary

This trial will test whether UVA1 phototherapy is an effective and safe treatment for vitiligo.

Who is the study for?

This trial is for adults over 18 with localized or generalized vitiligo, which isn't on mucosal or acral sites. They should have a patch of at least 25 cm2 with less than 10% repigmentation. It's not for those with severe illness, photosensitivity disorders, recent vitiligo treatments, history of skin cancer, or who are pregnant/breastfeeding.

What is being tested?

The study tests the effectiveness and safety of UVA1 phototherapy in treating vitiligo. This prospective single-blind randomized clinical trial compares patient outcomes to see how well UVA1 can improve the condition compared to other treatments.

What are the potential side effects?

While specific side effects aren't listed here, UVA1 therapy may cause skin irritation or increase sensitivity to sunlight. Long-term exposure could potentially raise risks for skin aging or cancer; however, these risks need further clarification within this context.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am older than 18 years.

Select...

I have vitiligo on areas of my skin that are not mucous membranes or on my hands and feet.

Select...

I have a skin area of at least 25 cm2 with less than 10% color return.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have a history of serious illness or a weak immune system.

Select...

I have a condition that makes my skin extra sensitive to sunlight.

Select...

I have had skin cancer in the past.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Active Control

Group I: No treatment (covered)Active Control1 Intervention

Group II: UVA1Active Control1 Intervention

0 / 6Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of British ColumbiaLead Sponsor

1,461 Previous Clinical Trials

2,485,182 Total Patients Enrolled

4 Trials studying Vitiligo

109 Patients Enrolled for Vitiligo

Harvey Lui, MD, FRCPCPrincipal InvestigatorUniversity of British Columbia

3 Previous Clinical Trials

64 Total Patients Enrolled

3 Trials studying Vitiligo

64 Patients Enrolled for Vitiligo

Media Library

UVA1 (Phototherapy) Clinical Trial Eligibility Overview. Trial Name: NCT01787695 — Phase 2

UVA1 (Phototherapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01787695 — Phase 2

Vitiligo Research Study Groups: No treatment (covered), UVA1

Vitiligo Clinical Trial 2023: UVA1 Highlights & Side Effects. Trial Name: NCT01787695 — Phase 2

~1 spots leftby Oct 2025

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.